Literature DB >> 29972637

NMR Measurements Reveal the Structural Basis of Transthyretin Destabilization by Pathogenic Mutations.

Benjamin I Leach1, Xin Zhang2, Jeffery W Kelly3, H Jane Dyson1, Peter E Wright1.   

Abstract

Inherited mutations of transthyretin (TTR) destabilize its structure, leading to aggregation and familial amyloid disease. Although numerous crystal structures of wild-type (WT) and mutant TTRs have been determined, they have failed to yield a comprehensive structural explanation for destabilization by pathogenic mutations. To identify structural and dynamic variations that are not readily observed in the crystal structures, we used NMR to study WT TTR and three kinetically and/or thermodynamically destabilized pathogenic variants (V30M, L55P, and V122I). Sequence-corrected chemical shifts reveal important structural differences between WT and mutant TTR. The L55P mutation linked to aggressive early onset cardiomyopathy and polyneuropathy induces substantial structural perturbations in both the DAGH and CBEF β-sheets, whereas the V30M polyneuropathy-linked substitution perturbs primarily the CBEF sheet. In both variants, the structural perturbations propagate across the entire width of the β-sheets from the site of mutation. Structural changes caused by the V122I cardiomyopathy-associated mutation are restricted to the immediate vicinity of the mutation site, directly perturbing the subunit interfaces. NMR relaxation dispersion measurements show that WT TTR and the three pathogenic variants undergo millisecond time scale conformational fluctuations to populate a common excited state with an altered structure in the subunit interfaces. The excited state is most highly populated in L55P. The combined application of chemical shift analysis and relaxation dispersion to these pathogenic variants reveals differences in ground state structure and in the population of a transient excited state that potentially facilitates tetramer dissociation, providing new insights into the molecular mechanism by which mutations promote TTR amyloidosis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29972637      PMCID: PMC6067956          DOI: 10.1021/acs.biochem.8b00642

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  41 in total

1.  Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans.

Authors:  D R Jacobson; R D Pastore; R Yaghoubian; I Kane; G Gallo; F S Buck; J N Buxbaum
Journal:  N Engl J Med       Date:  1997-02-13       Impact factor: 91.245

2.  Comparative calorimetric study of non-amyloidogenic and amyloidogenic variants of the homotetrameric protein transthyretin.

Authors:  V L Shnyrov; E Villar; G G Zhadan; J M Sanchez-Ruiz; A Quintas; M J Saraiva; R M Brito
Journal:  Biophys Chem       Date:  2000-12-15       Impact factor: 2.352

Review 3.  Nearly 200 X-ray crystal structures of transthyretin: what do they tell us about this protein and the design of drugs for TTR amyloidoses?

Authors:  S K Palaninathan
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

4.  NMRPipe: a multidimensional spectral processing system based on UNIX pipes.

Authors:  F Delaglio; S Grzesiek; G W Vuister; G Zhu; J Pfeifer; A Bax
Journal:  J Biomol NMR       Date:  1995-11       Impact factor: 2.835

5.  Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A.

Authors:  C C Blake; M J Geisow; S J Oatley; B Rérat; C Rérat
Journal:  J Mol Biol       Date:  1978-05-25       Impact factor: 5.469

6.  Amyloidogenic potential of transthyretin variants: insights from structural and computational analyses.

Authors:  Laura Cendron; Antonio Trovato; Flavio Seno; Claudia Folli; Beatrice Alfieri; Giuseppe Zanotti; Rodolfo Berni
Journal:  J Biol Chem       Date:  2009-07-14       Impact factor: 5.157

7.  Structure of the Val122Ile variant transthyretin - a cardiomyopathic mutant.

Authors:  A M Damas; S Ribeiro; V S Lamzin; J A Palha; M J Saraiva
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1996-09-01

8.  Fast and accurate fitting of relaxation dispersion data using the flexible software package GLOVE.

Authors:  Kenji Sugase; Tsuyoshi Konuma; Jonathan C Lansing; Peter E Wright
Journal:  J Biomol NMR       Date:  2013-06-11       Impact factor: 2.835

9.  The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.

Authors:  Z Lai; W Colón; J W Kelly
Journal:  Biochemistry       Date:  1996-05-21       Impact factor: 3.162

10.  Uncovering the Mechanism of Aggregation of Human Transthyretin.

Authors:  Lorena Saelices; Lisa M Johnson; Wilson Y Liang; Michael R Sawaya; Duilio Cascio; Piotr Ruchala; Julian Whitelegge; Lin Jiang; Roland Riek; David S Eisenberg
Journal:  J Biol Chem       Date:  2015-10-12       Impact factor: 5.157

View more
  11 in total

1.  Edge Strand Dissociation and Conformational Changes in Transthyretin under Amyloidogenic Conditions.

Authors:  Matthew C Childers; Valerie Daggett
Journal:  Biophys J       Date:  2020-10-20       Impact factor: 4.033

Review 2.  Transthyretin Misfolding, A Fatal Structural Pathogenesis Mechanism.

Authors:  Jin-Beom Si; Bokyung Kim; Jin Hae Kim
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

3.  Metal ions and redox balance regulate distinct amyloid-like aggregation pathways of GAPR-1.

Authors:  Jie Sheng; Nick K Olrichs; Willie J Geerts; Dora V Kaloyanova; J Bernd Helms
Journal:  Sci Rep       Date:  2019-10-21       Impact factor: 4.379

4.  Binding of Monovalent and Bivalent Ligands by Transthyretin Causes Different Short- and Long-Distance Conformational Changes.

Authors:  Alessandra Corazza; Guglielmo Verona; Christopher A Waudby; P Patrizia Mangione; Ryan Bingham; Iain Uings; Diana Canetti; Paola Nocerino; Graham W Taylor; Mark B Pepys; John Christodoulou; Vittorio Bellotti
Journal:  J Med Chem       Date:  2019-08-22       Impact factor: 7.446

Review 5.  A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis).

Authors:  Alejandra Gonzalez-Duarte; Alfredo Ulloa-Aguirre
Journal:  Int J Mol Sci       Date:  2021-12-06       Impact factor: 5.923

6.  High-avidity binding drives nucleation of amyloidogenic transthyretin monomer.

Authors:  Li Gao; Xinfang Xie; Pan Liu; Jing Jin
Journal:  JCI Insight       Date:  2022-04-08

7.  Biophysical characterization and modulation of Transthyretin Ala97Ser.

Authors:  Yo-Tsen Liu; Yueh-Jung Yen; Frans Ricardo; Yu Chang; Pei-Hao Wu; Shing-Jong Huang; Kon-Ping Lin; Tsyr-Yan Yu
Journal:  Ann Clin Transl Neurol       Date:  2019-09-10       Impact factor: 4.511

8.  Proposing a minimal set of metrics and methods to predict probabilities of amyloidosis disease and onset age in individuals.

Authors:  Richard S Criddle; Hsien-Jung L Lin; Isabella James; Ji Sun Park; Lee D Hansen; John C Price
Journal:  Aging (Albany NY)       Date:  2020-11-18       Impact factor: 5.682

9.  Mechanisms of Transthyretin Inhibition of IAPP Amyloid Formation.

Authors:  Sanduni Wasana Jayaweera; Solmaz Surano; Nina Pettersson; Elvira Oskarsson; Lovisa Lettius; Anna L Gharibyan; Intissar Anan; Anders Olofsson
Journal:  Biomolecules       Date:  2021-03-10

10.  Diphenyl-Methane Based Thyromimetic Inhibitors for Transthyretin Amyloidosis.

Authors:  Bokyung Kim; Young Ho Ko; Massimiliano Runfola; Simona Rapposelli; Gabriella Ortore; Grazia Chiellini; Jin Hae Kim
Journal:  Int J Mol Sci       Date:  2021-03-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.